IP Library Granted Patent US 9,511,134
Granted Patent B2
US 9,511,134 · App. 11/802,106 · Granted Dec 6, 2016

Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions

Inventors: Jeffery L. Alexander (San Diego, CA); Pamuk A. Bilsel (San Diego, CA); Mark J. Newman (Duluth, GA)
Assignee: Epimmune Inc.
A61K39/145A61K39/12A61K39/385A61K39/39C07K14/005A61K2039/53A61K2039/545A61K2039/55505A61K2039/55566A61K2039/605A61K2039/627C12N2760/16122C12N2760/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,511,134
App. No.
11/802,106
Granted
Dec 6, 2016
Kind
B2
Abstract

The present invention provides polynucleotides and polypeptides capable of enhancing the immune response of a human in need of protection against influenza virus infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an influenza protein or a fragment, variant, or derivative thereof, or at least one polypeptide encoded therefrom. The present invention also relates to identifying and preparing influenza virus epitopes and to polynucleotides and polypeptides comprising such influenza virus epitopes. The present invention also relates to compositions and methods of use in the prevention and treatment of influenza virus infection.

Claims (12)

1. An isolated immunogenic polynucleotide comprising:

(a) a nucleic acid encoding one to ten influenza HTL epitopes selected from the group of epitopes as set forth in Table 4;

(b) a nucleic acid encoding a pan-DR binding epitope;

(c) a nucleic acid encoding an influenza matrix protein 2 external (M2e) sequence selected from the sequences set forth in Table 6;

(d) a nucleic acid sequence encoding a polypeptide at least 90% identical to an influenza hemagglutinin (HA) sequence, or fragment thereof; and

(e) wherein the nucleic acid of (b) is located 5′ to the nucleic acid of (d); and wherein the polynucleotide enhances an immune response to influenza virus infection.

2. The isolated immunogenic polynucleotide of claim 1 , wherein said epitope from part (c) elicits a T-cell response.

3. The isolated immunogenic polynucleotide of claim 1 , wherein the polynucleotide is capable of inducing an immunogenic response.

4. A vector comprising the polynucleotide of claim 1 .

5. An immunogenic polypeptide encoded by the polynucleotide of claim 1 , wherein the polypeptide enhances an immune response to influenza virus infection.

6. An isolated cell comprising the polynucleotide of claim 1 .

7. An isolated cell comprising the vector of claim 4 .

Assignments (2)
CHANGE OF NAME Recorded Aug 8, 2012
From: PHARMEXA INC.
To: EPIMMUNE INC.
Reel/Frame 028747/0315 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 14, 2007
From: ALEXANDER, JEFFERY L.; BILSEL, PAMUK A.; NEWMAN, MARK J.
To: PHARMEXA INC.
Reel/Frame 019828/0246 →
Continuity (3)
Provisional Application 60801065 · May 18, 2006
Provisional Application 60838859 · Aug 21, 2006
Related Publication 20080032921A1 · Feb 7, 2008